Drugs / REGN9933
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07759167 | Sep 2026 → Apr 2027 expected | end stage renal failure | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06444178 | Sep 2024 → Apr 2025 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05102136 | Oct 2021 → Apr 2023 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT07175428 | Oct 2025 → Feb 2027 expected | atrial fibrillation | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT06299111 | Sep 2024 → Mar 2026 | venous thromboembolism | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT05618808 | May 2023 → May 2024 | venous thromboembolism | Regeneron Pharmaceuticals | Completed | Missed primary |
| Phase 33 trials | ||||||
| Phase 3 | NCT07697599 | Sep 2026 → Jun 2029 expected | venous thromboembolism | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07318610 | Jul 2026 → Aug 2029 expected | peripheral arterial disease | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07430956 | Apr 2026 → Mar 2029 expected | atrial fibrillation | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-12-19 | Regeneron Pharmaceuticals | Results Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results regeneron.com ↗
Per the Phase 2 results, there was a robust antithrombotic effect for each antibody, and no clinically relevant bleeding was observed in any treatment arm. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-12-19 | Regeneron Pharmaceuticals | Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results regeneron.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN9933 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07175428 ↗ |
| Action | Inhibit | “REGN9933A2 binds to the FXI apple 2 domain and blocks FXI activation by FXIIa.” PMID 41218619 ↗ Nov 2025 |
| Modality | Monoclonal antibody | “REGN9933, a Factor XI Monoclonal Antibody” NCT05618808 ↗ |
| Route | Intravenous | “REGN9933A2 (300 mg intravenously once)” PMID 41218619 ↗ Nov 2025 |